Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
27 févr. 2024 09h15 HE | Myriad Genetics, Inc.
SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a research collaboration with the National...
MNPR Triangle 2.JPG
Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
27 févr. 2024 07h00 HE | Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer...
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
26 févr. 2024 08h00 HE | Biora Therapeutics, Inc.
Data from SAD cohort expected to be shared during March corporate update; MAD cohorts to begin dosing in March.
Intrommune Therapeutics Presents Supporting Data Introducing a New Form of Food Allergy Treatment
22 févr. 2024 09h34 HE | Intrommune Therapeutics
OMIT (Oral Mucosal Immunotherapy) is a new approach to the management of food allergy demonstrating a robust immunologic response in treated subjects
Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19
21 févr. 2024 08h00 HE | BIOXYTRAN, INC.
First Medicinal chemistry of an antiviral drug made of sugars BOSTON, MASSACHUSETTS, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT), (the “Company”), a clinical stage biotechnology...
Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6
20 févr. 2024 04h00 HE | AKAMPION
- Designation underlines the need for novel, first-in-class antimicrobials for the treatment of infections with Gram-negative bacteria JERUSALEM, Israel, February 20, 2023 -- Omnix Medical, a...
Vaccinex logo
Vaccinex, Inc. Announces Reverse Stock Split
15 févr. 2024 08h00 HE | Vaccinex, Inc.
ROCHESTER, N.Y., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...
Nouveau Logo communiqué de presse.JPG
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
15 févr. 2024 07h30 HE | Theratechnologies
Study milestone further extends momentum for Company’s lead PDC candidate and oncology clinical development program MONTREAL, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc....
Nouveau Logo communiqué de presse.JPG
Theratechnologies complète le recrutement des six premières patientes de l’essai clinique de phase I mis à jour sur le sudocétaxel zendusortide dans le traitement du cancer de l’ovaire avancé
15 févr. 2024 07h30 HE | Theratechnologies
Une étape importante de l’étude afin de poursuivre l’élan pour le principal CPM de la Société et son programme de développement clinique en oncologie MONTRÉAL, 15 févr. 2024 (GLOBE...
Cybrexa Regains Rights to CBX-12
06 févr. 2024 08h00 HE | Cybrexa Therapeutics
NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a clinical-stage oncology biotechnology company developing a novel class of tumor-targeting peptide drug conjugate (PDC)...